Fifty consecutive patients with erectile failure who had previously proved refractory to papaverine and phentolamine intracavernosal therapy or were inappropriate candidates for such treatment were treated with intracavernosal prostaglandin E,. Forty patients (80%) achieved an erection sufficient forsexual intercourse and after a mean follow-up period of5.9 months, 32 patients were continuing to use treatment successfully. The average dose was 14 micrograms (range 2.5 to 30 micrograms). There were no cases of priapism or cavernosal fibrosis and no systemic side effects. A low incidence (8%) of local discomfort was reported. We conclude that prostaglandin is a safe and effective vasoactive agent for the treatment of erectile failure in a genito-urinary outpatient clinic.
INTRODUCTION
The use of intracavernous vasoactive agents has been shown to be effective in the medical treatment of erectile dysfunction. Virag ' originally described the use of the smooth muscle relaxant papaverine while Brindley 2 demonstrated the effectiveness of the alpha adrenergic receptor blocker phenoxybenzamine. A combination of papaverine plus phentolamine (an alpha-blocker) was subsequently shown to be more effective than either agent alone 3'4. Ishii 5 has described the use of prostaglandin-E1, and studies have since demonstrated its efficacy in association with a reduced incidence of serious side effects6 '7'8 We are unaware of reports of the use of this drug in a genito-urinary clinic, and describe our experience. PATIENTS AND METHODS Patients with erectile dysfunction were referred to the Genito-Clrinary Medicine Clinic, which provides a weekly clinic for erectile dysfunction, from their general practitioners or from consultant staff within the Northern Ireland hospital system. After a detailed sexual and medical history a full physical examination was performed and blood was taken for haemoglobin concentration, erythrocyte sedimentation rate, plasma glucose, liver function tests, testo-sterone and prolactin measurement. Intracavernous Prostaglandin El was first used in this clinic in November 1991, and this paper describes the first 50 patients. Those selected fulfilled one or more of the following criteria: (1) Previous failure to achieve satisfactory erectile response to papaverine 30 mg plus phentolamine 1 mg. (2) Previous priapism associated with papaverine plus phentolamine treatment or (3) Patients with a history of serious ischaemic heart disease but who were currently stable. The latter group of patients were assessed by a consultant cardiologist to ensure that treatment for their impotence was appropriate. Intracavernous injection of 10 ,ug of prostaglandin was given with a fine bore needle (26 gauge) into the lateral aspect of one of the corpora cavernosa at a site 1-2 cms proximal to the coronal sulcus. It was not our routine practice to use a constricting band at the base of the penis at the time of injection. The drug was supplied in 1 ml ampoules containing 10 jg prostaglandin El. These were individually prepared at the pharmacy of the Royal Victoria Hospital from 500,g ampoules (Upjohn). The initial dosage was 10 ,ug with appropriate titration according to response up to a maximum of 30 ,ug. Once an erection sufficient for sexual intercourse was achieved the patient was instructed in the technique of self-injection and supervised to ensure that their technique was correct. A supply of needles, syringes and prostaglandin El, was then provided for home use with advice that the injection should not be used more than twice per week; the patient attended on a regular basis to monitor effectiveness, side effects and to provide new supplies. Those who did not achieve an erection sufficient for sexual intercourse despite maximal dosage of 30 jig were assessed for a mechanical suction device. RESULTS Fifty patients satisfied the criteria for treatment between November 1991 and September 1992. This represented approximately one third of patients on intracavernosal treatment. Their average age was 52.5 years (range 25-74) with a mean duration of impotence of 5.7 years (range 6 months -30 years). The aetiology was organic in 44 cases, psychogenic in 3 cases and uncertain in three cases (Table 1) . Five patients had had previous episodes of priapism. through the lungs 12. It is this rapid elimination which is believed to account for the absence of systemic side effects even in the presence of venous leakage. Many reports on its clinical use have shown a notable absence of priapism or fibrosis 5, 8, 9. Some authors,, however, have documented priapism requiring treatment with metaraminol 10,' the most vulnerable group being those with a non-vasculogenic aetiology. Cases of sustained erections of up to 11 hours have also been described where spontaneous detumescence ultimately occurred 6 1O. In our own series there were no cases of priapism or sustained erection and this may be related to the selection of patients with vasculogenic disease. Corporeal fibrosis and fibrotic thickening of the tunica albuginea have been reported with papaverine injections and may be related to a number of factors including repetitive needle trauma, organization of haematomas associated with vascular puncture, or a local toxic reaction to papaverine solution which is of low pH 1316. We found no cases of corporeal fibrosis although the period of follow-up at present is relatively short. In previous studies the most commonly described side effect of prostaglandin El is the occurrence of localized pain in the penis, varying in intensity from mild discomfort to a severe burning sensation prohibiting sexual intercourse. The reported incidence varies from 11% up to 75% 6-10, but was a complaint in only four patients (8%) in our own series. In only one was a dose reduction required to ameliorate this problem. Localized pain appears to occur more commonly in those individuals whose impotence is non-vasculogenic in origin 10, which may explain the low incidence of this series. Intracavernous prostaglandin E, has proved an effective and safe alternative agent for the treatment of erectile failure with particular application to those patients where treatment with papaverine and phentolamine had been ineffective or inappropriate.
